Article
Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and…
eLife · 2017 · Justin M Jenson, author Jeremy A Ryan, author Robert A Grant, author Anthony Letai, author Amy E Keating, author
Key facts
| Title | Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1 |
|---|---|
| First author | Justin M Jenson, author Jeremy A Ryan, author Robert A Grant, author Anthony Letai, author Amy E Keating, author |
| Journal | eLife |
| Published | Jun 8, 2017 |
| DOI | 10.7554/eLife.25541 |
| Devices mentioned | BK110039, K202641, K231013 |
| Product codes mentioned | KIT, MVU, NJT, PFF, PFT, PCA, QBD |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1